Anuh Pharma

Why is Anuh Pharma Ltd falling/rising?

As of 20-Jun, Anuh Pharma Ltd's stock price is Rs 77.64, down 1.47%, reflecting a downward trend with a total decline of 5.43% over the last three days. The stock has underperformed the Sensex and shows weak financial metrics, indicating a lack of investor confidence and sustained buying interest.

As of 20-Jun, Anuh Pharma Ltd's stock price is falling, currently at Rs 77.64, reflecting a decrease of Rs 1.16 or 1.47%. The stock has been on a downward trend, having underperformed its sector by 2.98% today and experiencing a consecutive fall over the last three days, resulting in a total decline of 5.43% during this period. <BR><BR>Despite opening with a gain of 3.38% today and reaching an intraday high of Rs 81.46, the stock quickly fell to a low of Rs 77.02, indicating significant volatility and a lack of sustained buying interest. The trading volume has also decreased, with delivery volume dropping by 60.83% compared to the five-day average, suggesting falling investor participation.<BR><BR>In terms of performance metrics, Anuh Pharma has underperformed the benchmark Sensex across multiple time frames, including a 1-year return of -25.24% compared to the Sensex's -5.60%. The company's financials show a decline in profits by 13.3% over the past year, alongside poor long-term growth indicators, such as net sales and operating profit growth rates of only 12.30% and 11.02%, respectively, over the last five years. <BR><BR>Additionally, the stock is trading below its moving averages across various time frames, which typically signals a bearish trend. The lack of investment from domestic mutual funds, holding 0% of the company, further indicates a lack of confidence in the stock's future performance. Overall, these factors contribute to the stock's current decline.

Which are the latest news on Anuh Pharma?

What does Anuh Pharma do?

Anuh Pharma Ltd is a micro-cap manufacturer of Active Pharmaceutical Ingredients (APIs) in the Pharmaceuticals & Biotechnology sector, reporting net sales of 202 Cr and a net profit of 12 Cr for the quarter ending March 2026. The company is part of the SK Group and has a market cap of INR 787 Cr.

Overview:<BR>Anuh Pharma Ltd is a leading manufacturer of Active Pharmaceutical Ingredients (APIs) in the Pharmaceuticals & Biotechnology industry, categorized as a Micro Cap company.<BR><BR>History:<BR>Anuh Pharma Ltd was incorporated in an unspecified year and is part of the SK Group. The latest quarterly results reported net sales and net profit for the period ending March 2026.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 202 Cr (Quarterly Results - Mar 2026) <BR>Most recent Net Profit: 12 Cr (Quarterly Results - Mar 2026) <BR>Market-cap value: INR 787 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: 18.00 <BR>Industry P/E: 34 <BR>Dividend Yield: 1.95% <BR>Debt-Equity: -0.15 <BR>Return on Equity: 11.65% <BR>Price to Book: 2.19 <BR><BR>Contact Details:<BR>Address: 3-A Shivsagar Estate, North Wing Dr A B Road Worli Mumbai Maharashtra : 400018 <BR>Tel: 91-22-6622 7575 <BR>Email: anuh@sk1932.com <BR>Website: http://www.anuhpharma.com

How big is Anuh Pharma?

As of 10th June, Anuh Pharma Ltd has a market capitalization of 787.00 Cr and reported Net Sales of 138.83 Cr with a Net Profit loss of 0.00 Cr in the latest two quarters. Shareholder's Funds are 326.02 Cr and Total Assets amount to 504.55 Cr as of March 2025.

As of 10th June, Anuh Pharma Ltd has a market capitalization of 787.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest two quarters, the company reported Net Sales of 138.83 Cr. The Net Profit for the same period was a loss of 0.00 Cr.<BR><BR>The latest annual period for the balance sheet is March 2025, with Shareholder's Funds amounting to 326.02 Cr and Total Assets of 504.55 Cr.

Who are in the management team of Anuh Pharma?

The management team of Anuh Pharma includes Bipin N Shah (Vice Chairman), Ritesh B Shah and Vivek B Shah (Joint Managing Directors), and several independent and non-executive directors, totaling 15 members, including Hemant Auti as Company Secretary. This diverse team ensures effective governance and leadership for the company.

The management team of Anuh Pharma includes the following individuals:<BR><BR>1. **Bipin N Shah** - Vice Chairman<BR>2. **Ritesh B Shah** - Joint Managing Director<BR>3. **Vivek B Shah** - Joint Managing Director<BR>4. **Jasvantlal Shah** - Chairman & Independent Director<BR>5. **Arun L Todarwal** - Non-Executive & Independent Director<BR>6. **Harmanbhai Tulsibhai Patel** - Non-Executive & Independent Director<BR>7. **Sandeep M Joshi** - Non-Executive & Independent Director<BR>8. **Pradeep Thakur** - Independent Director<BR>9. **Siddharth Shah** - Independent Director<BR>10. **Gaurav Shah** - Independent Director<BR>11. **Bharat N Shah** - Non-Executive & Non-Independent Director<BR>12. **Samir J Shah** - Non-Executive & Non-Independent Director<BR>13. **Ketan L Shah** - Non-Executive & Non-Independent Director<BR>14. **Mita Dixit** - Non-Executive & Non-Independent Director<BR>15. **Hemant Auti** - Company Secretary & Compliance Officer<BR><BR>This team comprises a mix of executive and non-executive members, with a range of independent directors contributing to the governance of the company.

Who are the peers of the Anuh Pharma?

Anuh Pharma's peers include Kopran, Sigachi Industries, Anlon Healthcare, Shree Ganesh Rem, Kilitch Drugs, Zim Laboratories, Amanta Healthcare, Jenburkt Pharma, Influx Health, and Remus Pharma. Anuh Pharma has average management risk, a below-average growth outlook, and a 1-year return of -27.10%.

Peers: The peers of Anuh Pharma are Kopran, Sigachi Indust., Anlon Healthcare, Shree Ganesh Rem, Kilitch Drugs, Zim Laboratories, Amanta Healthcar, Jenburkt Pharma, Influx Health, and Remus Pharma.<BR><BR>Quality Snapshot: Excellent management risk is observed at Jenburkt Pharma, while Average management risk is found at Kopran, Sigachi Indust., Anuh Pharma, Anlon Healthcare, Shree Ganesh Rem, Zim Laboratories, Amanta Healthcar, Influx Health, and Remus Pharma, and Below Average management risk is noted at Kilitch Drugs. Growth is Excellent at Anlon Healthcare and Kilitch Drugs, while Below Average growth is seen at Kopran, Sigachi Indust., Anuh Pharma, Shree Ganesh Rem, Zim Laboratories, Amanta Healthcar, and Jenburkt Pharma, and the rest. Capital Structure is Excellent at Sigachi Indust., Anuh Pharma, Shree Ganesh Rem, Influx Health, and Jenburkt Pharma, Good at Kopran and Anlon Healthcare, and Below Average at Amanta Healthcar.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Zim Laboratories at 4.71%, while Sigachi Indust. has the lowest at -62.71%. Anuh Pharma's 1-year return is -27.10%, which is higher than Sigachi Indust. but lower than Zim Laboratories. Additionally, Amanta Healthcar and Influx Health have a six-month return of 0.00%.

Should I buy, sell or hold Anuh Pharma Ltd?

Are Anuh Pharma Ltd latest results good or bad?

Anuh Pharma Ltd's latest results show strong revenue growth of 22.91% and a record net profit of ₹13.45 crores, but declining operating margins and a 21.55% stock decline raise concerns about profitability and market performance, suggesting a cautious outlook.

Anuh Pharma Ltd's latest results present a mixed picture. On the positive side, the company reported a significant revenue growth of 22.91% year-on-year for the nine months of FY26, totaling ₹569.54 crores. Additionally, the net profit for Q3 FY26 reached ₹13.45 crores, marking the highest quarterly profit in the company's history.<BR><BR>However, there are concerning trends regarding profitability. The operating margin has compressed, dropping from 11.6% in FY24 to 9.2% in FY25, indicating pressure on margins due to rising operational costs or pricing pressures in the market. Furthermore, the Return on Capital Employed (ROCE) has declined to 15.90%, the lowest in the tracked period, raising questions about the company's efficiency in generating returns from its capital.<BR><BR>The stock has also underperformed the broader market, with a 21.55% decline over the past year, which is significantly worse than the Sensex's positive return. This underperformance reflects investor concerns about the sustainability of earnings quality amid the margin pressures.<BR><BR>In summary, while Anuh Pharma has shown strong revenue growth and achieved a record net profit, the declining margins and overall underperformance in the market suggest that the results are not entirely positive and warrant caution moving forward.

Is Anuh Pharma technically bullish or bearish?

As of December 2, 2025, Anuh Pharma's trend has shifted to a bearish stance with moderate strength, driven by bearish MACD and moving averages, alongside mixed signals from Bollinger Bands and KST, indicating a negative outlook for the stock.

As of 2 December 2025, the technical trend for Anuh Pharma has changed from mildly bearish to bearish. The current stance is bearish with moderate strength. Key indicators driving this include a bearish MACD on the weekly chart, bearish moving averages on the daily timeframe, and mildly bearish signals from Bollinger Bands on both weekly and monthly charts. The KST shows a mildly bullish signal on the weekly but is mildly bearish on the monthly, indicating mixed signals in the short term. Overall, the lack of strong bullish momentum and the prevailing bearish indicators suggest a negative outlook for the stock.

How has been the historical performance of Anuh Pharma?

Anuh Pharma has shown consistent growth in net sales, increasing from 306.96 Cr in Mar'20 to 661.51 Cr in Mar'25, despite recent declines in profitability metrics. Total assets also grew significantly, while cash flow from operating activities improved notably in the same period.

Answer:<BR>The historical performance of Anuh Pharma shows a consistent growth trajectory in net sales and profitability over the years.<BR><BR>Breakdown:<BR>Anuh Pharma's net sales have steadily increased from 306.96 Cr in Mar'20 to 661.51 Cr in Mar'25, reflecting a strong upward trend. Total operating income followed a similar pattern, rising from 306.96 Cr in Mar'20 to 661.51 Cr in Mar'25. The raw material cost peaked at 489.73 Cr in Mar'24 but decreased to 463.28 Cr in Mar'25, indicating improved cost management. Operating profit (PBDIT) saw fluctuations, peaking at 87.24 Cr in Mar'24 before dropping to 70.36 Cr in Mar'25. Profit before tax also experienced a decline from 78.31 Cr in Mar'24 to 61.01 Cr in Mar'25, while profit after tax decreased from 60.06 Cr to 47.35 Cr in the same period. The company's total assets grew from 326.37 Cr in Mar'20 to 504.55 Cr in Mar'25, with total liabilities increasing from 326.37 Cr to 504.55 Cr as well. Cash flow from operating activities improved significantly from 12.00 Cr in Mar'24 to 37.00 Cr in Mar'25, contributing to a net cash inflow of 12.00 Cr in Mar'25, up from 5.00 Cr in Mar'24. Overall, Anuh Pharma's financials indicate a robust growth trajectory, despite some recent declines in profitability metrics.

Who are the top shareholders of the Anuh Pharma?

The top shareholders of Anuh Pharma are primarily its promoters, with Bharti Bipin Shah holding the largest stake at 19.43%. Individual investors own 25.92% of the shares, while foreign institutional investors hold a minimal 0.04%, and there are no pledged promoter holdings.

The top shareholders of Anuh Pharma primarily consist of its promoters, with Bharti Bipin Shah being the individual with the highest holding at 19.43%. Additionally, individual investors collectively hold 25.92% of the company's shares. There are no mutual funds involved, and foreign institutional investors (FIIs) hold a minimal stake of 0.04% through three different entities. Notably, there are no pledged promoter holdings, indicating a strong commitment from the promoters.

What is the bonus history of Anuh Pharma?

Anuh Pharma has a history of issuing bonus shares, including a recent 1:1 bonus announced for July 15, 2025, and previous bonuses of 1:1 in September 2020, 2:1 in August 2015, 2:1 in October 2010, and 1:1 in August 2006. This reflects the company's commitment to rewarding shareholders.

Anuh Pharma has a notable history of bonus issues. Here’s a summary of their bonus announcements:<BR><BR>1. **Latest Bonus**: A 1:1 bonus issue was announced, with an ex-date of July 15, 2025.<BR> <BR>2. **Previous Bonuses**:<BR> - On September 21, 2020, a 1:1 bonus was issued, with the ex-date on September 18, 2020.<BR> - On August 6, 2015, the company issued a 2:1 bonus, with the ex-date on August 5, 2015.<BR> - On October 29, 2010, another 2:1 bonus was issued, with the ex-date on October 28, 2010.<BR> - The earliest in this history was a 1:1 bonus on August 7, 2006, with the ex-date on July 31, 2006.<BR><BR>This history reflects Anuh Pharma's approach to rewarding its shareholders through bonus shares over the years.

Is Anuh Pharma overvalued or undervalued?

As of April 8, 2025, Anuh Pharma's valuation has shifted to attractive, with a PE ratio of 22.36, an EV to EBITDA of 16.77, and a ROCE of 23.53%, indicating it is fairly valued compared to peers despite a recent 1-year return of -4.51% against the Sensex's 7.60%.

As of 8 April 2025, Anuh Pharma's valuation grade has moved from very attractive to attractive, indicating a shift in its perceived investment quality. The company appears to be fairly valued at this time. Key ratios include a PE ratio of 22.36, an EV to EBITDA of 16.77, and a ROCE of 23.53%. <BR><BR>In comparison to its peers, Anuh Pharma's PE ratio is in line with the industry average, while its EV to EBITDA is also competitive. Notable peers include a company with a PE of 22.5 and another with an EV to EBITDA of 17.0. Despite recent underperformance against the Sensex, with a 1-year return of -4.51% compared to the Sensex's 7.60%, the company's strong fundamentals suggest it is positioned well within the pharmaceuticals and biotechnology sector.

When is the next results date for Anuh Pharma?

No Upcoming Board Meetings

Has Anuh Pharma declared dividend?

Anuh Pharma Ltd has declared a 50% dividend, amounting to ₹2.5 per share, with an ex-date of August 16, 2024. While recent performance shows declines in the short term, the company has delivered positive total returns over longer periods, particularly in the 2 and 3-year spans.

Anuh Pharma Ltd has declared a 50% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 50%<BR>- Amount per share: 2.5<BR>- Ex-date: 16 Aug 24<BR><BR>Dividend Yield: 1.19%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was -4.38%, with no dividend return, resulting in a total return of -4.38%.<BR><BR>Over the past year, the price return was -4.35%, with a dividend return of 1.08%, leading to a total return of -3.27%.<BR><BR>In the 2-year period, the price return was 136.42%, with a dividend return of 4.02%, resulting in a total return of 140.44%.<BR><BR>For the 3-year period, the price return was 127.47%, with a dividend return of 7.41%, culminating in a total return of 134.88%.<BR><BR>In the last 4 years, the price return was 57.33%, with a dividend return of 5.62%, leading to a total return of 62.95%.<BR><BR>Over the 5-year period, the price return was 110.42%, with a dividend return of 7.11%, resulting in a total return of 117.53%.<BR><BR>Overall, Anuh Pharma has declared a dividend, contributing positively to returns over longer periods, particularly in the 2 and 3-year spans, while recent performance shows a decline in the shorter term.